Habitrol labeling changes
This article was originally published in The Tan Sheet
FDA approves supplemental NDA 20-076/S-021 for labeling changes to Novartis' Habitrol smoking cessation patch on July 15. New packaging will incorporate current pregnancy/breastfeeding warning, as requested by FDA in 2001 (1"The Tan Sheet" August 27, 2001, p. 3). Changes will appear on "Drug Facts" box of 7 mg, 14 mg and 21 mg Habitrol cartons. Revised labeling also will be reflected on multi-dose Habitrol kit, which was approved as the first 3-in-1 smoking cessation offering in July (2"The Tan Sheet" July 22, 2002, p. 4)...
You may also be interested in...
Novartis Consumer Healthcare's Habitrol multi-dose smoking cessation kit will represent the first time an entire course of nicotine replacement therapy is available in a single package
OTC nicotine-replacement therapy manufacturers who wish to use a pregnancy/breastfeeding warning different from new, FDA-revised labeling "will have to provide data to support alternative wording," the agency says.
Acoramidis, AstraZeneca/BridgeBio Pharma's investigational treatment for patients with transthyretin amyloid cardiomyopathy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.